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Abstract
Background: Graves’ orbitopathy (GO) is an autoimmune condition, which is associated with poor clinical
outcomes including impaired quality of life and socio-economic status. Current evidence suggests that the
incidence of GO in Europe may be declining, however data on the prevalence of this disease are sparse. Several
clinical variants of GO exist, including euthyroid GO, recently listed as a rare disease in Europe (ORPHA466682).
The objective was to estimate the prevalence of GO and its clinical variants in Europe, based on available literature,
and to consider whether they may potentially qualify as rare. Recent published data on the incidence of GO and
Graves’ hyperthyroidism in Europe were used to estimate the prevalence of GO. The position statement was
developed by a series of reviews of drafts and electronic discussions by members of the European Group on
Graves’ Orbitopathy. The prevalence of GO in Europe is about 10/10,000 persons. The prevalence of other clinical
variants is also low: hypothyroid GO 0.02–1.10/10,000; GO associated with dermopathy 0.15/10,000; GO associated
with acropachy 0.03/10,000; asymmetrical GO 1.00–5.00/10,000; unilateral GO 0.50–1.50/10,000.
Conclusion: GO has a prevalence that is clearly above the threshold for rarity in Europe. However, each of its
clinical variants have a low prevalence and could potentially qualify for being considered as a rare condition,
providing that future research establishes that they have a distinct pathophysiology. EUGOGO considers this area of
academic activity a priority.
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Background
Graves’ orbitopathy (GO) (ICD-10 H06.2) [1] is an auto-
immune condition that targets the orbits [2] and is re-
sponsible for significant morbidity [3, 4] including, in rare
cases, blindness [5]. The pathogenesis of GO is closely
linked to thyroid autoimmunity [2]. Autoimmune thyroid
diseases share a common genetic background, but display
widely varying and overlapping clinical phenotypes [6].
Among them, GO is the most striking extra-thyroidal
manifestation and the hardest to treat [5, 7]. GO has been
described as a rare disease by several authors [8–12], how-
ever meaning “uncommon” without a precise definition
and to date no direct population surveys of prevalence are
available. Rare disease status can raise public awareness
and encourage research, leading to improved patient care
[13], much of which is needed for patients with GO [14].
The objective of this position statement was to estimate
the prevalence of GO and its clinical variants in Europe,
based on available literature, and to explore whether rare
disease designation may be appropriate.
Methods
A task force was identified by the officers of the European
Group on Graves’ Orbitopathy (EUGOGO). The lead
author performed a literature search using PubMed with
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the key terms “Graves’ orbitopathy”, “Graves’ ophthalmopa-
thy”, “thyroid eye disease” and “prevalence”, “epidemiology”,
“incidence”, “rare disease”, “orphan”. Based on the results of
the literature search, a brief review of the available evidence
and a list of questions relevant to the topic of GO as a rare
disease was drafted and circulated to members of the task
force for approval. All members of EUGOGO were invited
to contribute if they so wished. Topics were allocated to in-
dividual authors who were asked to perform additional lit-
erature searches and summarise, appraise and comment on
the evidence. The submissions from individual members
were circulated for review and comment, leading to further
discussions, amendments and the final draft.
The prevalence of GO was estimated from publications
on the incidence of GO and Graves’ hyperthyroidism
(ICD-10, E05.0) [1]. The literature search was limited to
studies of patient cohorts derived from European popula-
tions that completed recruitment after 2005, in order to
capture most recent trends given that the focus of our
interest is Europe, and that the epidemiology of GO seems
to be changing over time [11, 15–17]. The literature
search on the incidence of Graves’ hyperthyroidism
yielded 366 publications. Of these, only three studies met
the above criteria [18–20]; Table 1.
The prevalence of Graves’ hyperthyroidism, from inci-
dence data, was estimated using established methodolo-
gies for calculating global burden of disease [21–23] and
the software DisMod II [24]. This is based on a simple
model that formalises the relation between incidence
(age and sex adjusted), general mortality, case-fatality and
prevalence. We assumed that the duration of GO is life-
long (though some cases of GO are transient, but difficult
to quantify) and that the relative risk of dying due to
Graves’ hyperthyroidism is 1.28 (95% CI 1.21-1.36), based
on data from Brandt et al. [25]. It was further assumed
that within the general population an individual will either
acquire GO, or die from a GO-unrelated cause; that pa-
tients with GO will either die from a GO-related, or from
a GO-unrelated cause; and that the influence of the inci-
dence of a rare disease on the general population is negli-
gible. It follows that the number of subjects within a stable
general population at any given moment will depend on
the mortality rate and GO incidence, while the number of
GO patients will depend on GO incidence, case fatality
and general mortality rate. If GO incidence, case fatality
and general mortality rate are constant, a set of ordinary
differential equations can be defined to characterise move-
ment between general population, diseased, and dead [24].
Results and discussion
The available data on incidence of GO and Graves’ dis-
ease in Europe are limited, but are derived from different
geographical areas, are large and internally consistent,
and therefore reliable for the purposes of estimating
prevalence of GO.
Calculation of prevalence of GO from incidence of GO
The data provided by one of the major publications on
the incidence of GO [20] did not include age-specific in-
tervals. However, the authors stated that “age distribu-
tion differed in GO and Graves’ hyperthyroidism, with
GO being less than 2% of Graves’ hyperthyroidism at
age 20–40 year and 8% at age 40–60 year.” We therefore
estimated age and sex-specific incidences derived from
[20] and used them to calculate prevalence (Table 2).
This is the only study which directly assessed the inci-
dence of GO in a large European population prospectively
and included new cases between 1992 and 2011, based on
approximately 8.9 million person-years of observation
[20]. The incidence of moderate-to-severe GO was 0.161/
10,000/year with a median age at onset of 50 years [20].
Mild cases of GO were not included due to difficulties in
defining mild GO in large-scale epidemiological surveys.
Distinguishing mild GO from normality and from the
transient ocular effects of thyrotoxicosis of any cause,
can be a challenge, especially if multiple observers are
involved with variable degrees of expertise. In recent
cross-sectional studies from secondary or tertiary cen-
tres, conducted by highly trained observers and with
well-defined criteria for GO, about 65% of all cases of
GO were found to have mild GO, and about 2% sight-
threatening, disease [11, 16]. We assumed that the
cases of mild GO which were excluded by Laurberg
et al. [20], accounted for 2/3 (65%) of all cases of GO.
Hence, the adjusted figure for incidence of all grades of
severity of GO, based on the above studies [11, 16, 20],
is 0.483/10,000/year (incidence of moderate-to-severe
disease 0.161 multiplied by 3, in view of the fact that it
represents 1/3 of all cases = 0.483). The data published
by Laurberg et al. [20] are unclear as to whether sight-
Table 1 Characteristics of studies selected for estimation of prevalence of GO
Study Study population Country Years studied Type of study
Abraham-Nordling et al. [18] 3.5 million general
population
Sweden 2003–2005 Prospective, population registry-based, reporting on incidence
of Graves’ hyperthyroidism and all grades of severity of GO
Zaletel et al. [19] 1.0 million general
population
Slovenia 1999–2009 Single institution, prospective cohort study of patients with
thyroid disease, including Graves’ hyperthyroidism as a subgroup
Laurberg et al. [20] 0.5 million general
population
Denmark 1992–2011 Single institution, prospective cohort study, reporting on
incidence of moderate-to- severe GO
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threatening GO was included within the moderate-to-
severe category. We therefore used the frequency of
sight-threatening GO of 2% cited by other publications
[11, 16] to calculate the prevalence of sight-threatening
GO from data by [20]. Using the approach described in
“methods” the prevalence of GO is estimated to be
8.97/10,000 population. It can be further broken down
to mild (5.83/10,000), moderate-to-severe (2.96/10,000)
and sight-threatening GO (0.18/10,000) (Table 3a).
Calculation of prevalence of GO from incidence of Graves’
hyperthyroidism
Based on data for incidence of Graves’ hyperthyroidism,
the calculated incidence of GO in Europe has been re-
ported to be 10–30/10,000/year [26–28]. These studies re-
late to epidemiological data collected 10–20 years ago and
the estimates may not be valid today since the incidence of
GO appears to be declining [11, 14, 15] although this may
be partly due changing referral patterns. In a recent study,
Abraham-Nordling et al. [18] reported the incidence of
Graves’ hyperthyroidism derived from a Swedish population
of about 3.5 million. The incidence of Graves’ hyperthyroid-
ism was 2.10/10,000/year. Mild (“non-infiltrative”) GO was
present in 15.2% of patients with Graves’ hyperthyroidism
and moderate-to-severe/sight-threatening (infiltrative) in
4.9% of cases. Thus, the incidence of all cases of GO was
0.42/10,000/year (incidence of mild GO 0.32/10,000/year
and of moderate-to-severe/sight-threatening 0.10/10,000/
year) [18]. Using the same methodology for calculating
prevalence as before, the prevalence of GO is shown in
Table 3a. The study by Zaletel et al. [19] yielded remarkably
similar results for the incidence of Graves’ hyperthyroidism
as that by Abraham-Nordling et al. [18] (2.08/10,000/year),
and identical figures for the prevalence of GO (Table 3a).
The figures for overall prevalence of GO derived from
[18] and [20] vary almost by a factor of 2. The reason is
unclear but it may represent a true variation in different
populations, or may be accounted for by the different
methodologies in identifying cases. Laurberg et al. [20]
presumed that all patients with moderate-to-severe GO
were seen in a single tertiary centre. Hence, the data
have included some patients with GO seen elsewhere
and patients who were not referred. The other study
[18] identified patients with Graves’ hyperthyroidism
through a registry and it may have captured more cases.
One of the weaknesses of our calculations is that the
estimates of prevalence of GO are derived from a small
(n = 3) number of epidemiological studies. However,
this is all that is available in the recent literature and it
is unlikely that more extensive data will be forthcoming
for a while. The consistency between the figures from
the three studies quoted above is sufficient in our view
to justify estimates of prevalence based on these data.
Prevalence of variants of GO
A number of distinct clinical variants of GO exist, however
these are poorly studied and deserve attention. Euthyroid/
Table 2 Estimated age and sex-specific incidences derived
from Laurberg et al. [20]. These figures were used to calculate
prevalence of GO
Age (years) Incidence of GO (cases/10,000/year)
Female Male
0–20 2.7 0.005
20–40 6.7 0.014
40–60 26.7 0.054
>60 13.4 0.027
Table 3 Estimated prevalence of GO and variants of GO. (a) shows prevalence by severity and (b) for clinical variants (all grades of
severity)
PREVALENCE (per 10,000 population) PROPORTION OF PATIENTS WITH VARIANT SOURCE
(a)
All cases of GO 8.97 - [18]
15.48 [19, 20]
Mild GO 5.83 65.0% [18]
11.03 72.8% [19, 20]
Moderate-to-severe 2.96–4.45 33.0–29.4% [18–20]
Sight-threatening 0.18 2.0% [11, 14]
(b)
Euthyroid/hypothyroid GO 0.02–1.10 0.2–11.0% [29–33]
GO associated with dermopathy 0.15 1.5% [7]
GO associated with acropachy 0.03 0.3% [7]
Asymmetrical GO 1.00–5.00 10.0–50.0% [34–36]
Unilateral GO 0.50–1.50 5.0–15.0% [35–38]
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hypothyroid GO is a variant comprising of patients who are
euthyroid, or have overt or subclinical hypothyroidism, be-
fore or within 6–12 months after the onset of GO and con-
stitutes 0.2–11% of all cases of GO [29–33]. Patients with
GO associated with dermopathy have characteristic skin
changes and comprise 1.5% of all cases of GO [7]. Patients
with GO associated with acropachy display typical nail and
subperiosteal changes and make up 0.3% of all cases of GO
[7]. Asymmetrical GO, usually defined as a difference of
≥2 mm in proptosis between the two eyes, is reported to
occur in 10–50% of patients with GO [30, 34–36]. Unilat-
eral GO, defined as one of more features of GO in one eye
without any in the contralateral eye, is reported to occur
with a frequency of 5–15% of all cases of GO [35–38]. Pre-
viously reported data on the frequency of euthyroid and
asymmetrical/unilateral GO are likely to be overestimates
as awareness of IgG4-related ophthalmic disease has been
low [39, 40], but is impossible to quantify. The estimated
prevalence of these variants (inclusive of all grades of sever-
ity) based on the previously estimated overall prevalence of
GO of approximately 10/10,000 population, and the re-
ported frequencies of the variants is shown in Table 3b.
One of our assumptions in calculating the prevalence
of GO was that the duration of GO is life-long. In a minor-
ity of patients this is not the case. In a study published
20 years ago by Bartley et al. [41], 40% of patients respond-
ing by questionnaire reported that their eyes were normal
10 years after the diagnosis of GO, but this was not possible
to confirm objectively. A study published in 2002 by Ter-
wee and colleagues [42] reported on outcomes in a cohort
of patients after 11.7 years of follow-up, but the data did
not report on the frequency of complete regression of the
features of GO. In a more recent study a significant propor-
tion of patients had transient GO [11]. However, this was a
selected group of patients with Graves’ hyperthyroidism
who had no GO at the time of recruitment and were
treated with anti-thyroid drugs, from a single institution. It
is therefore impossible to correct for transient GO with an
acceptable degree of confidence without taking a risk to
over-state the case for variants of GO being rare. However,
it is important to highlight that the data in Table 3 are likely
to be overestimates of the prevalence of GO.
Designation of rare disease in Europe requires that
several conditions be satisfied: prevalence of less than 5
per 10,000 population [43], distinct phenotype, distinct
aetiology and mechanism of pathogenesis [44] and ser-
iously debilitating or life-threatening impact on patients
[45]. Euthyroid GO achieved rare disease status on the
basis of the above criteria, and the consideration that the
euthyroid status of such patients reflects mechanistically
unique processes that are distinct from Graves’ hyperthy-
roidism. We speculate that the other clinical variants de-
scribed above may also have underlying unique and distinct
pathogenetic processes from Graves’ hyperthyroidism and
each other. Future research focusing on deep phenotyping
and molecular characteristics of variants of GO is likely to
be productive in understanding the pathogenesis of GO.
Conclusions
GO has a prevalence that is clearly above the threshold
for rarity in Europe. However, each of its clinical variants
have a low prevalence and could potentially qualify for
being considered as a rare condition, providing that fu-
ture research establishes that they have a distinct patho-
physiology. EUGOGO considers this area of academic
activity a priority.
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